Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial
Anna Nilson, Patricia Couroux, Jaana Haka, Silja Halme et autres
ABSTRACT Background This paper reports a Phase 1, randomised, placebo‐controlled, dose‐escalation trial (NCT06037148) with DM‐101PX that contains a recombinant hypoallergenic Bet v 1 variant formulated with thermosensitive hydrogel. The objectives of the study included assessment of treatment‐related adverse events and the number …
fi, nl, gb (code pays fourni par la source)
0 citations
Clinical & Experimental Allergy